---
title: "Kardigan (KARD) news: going concern and IPO"
url: "https://aibio.space/companies/kardigan/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "KARD going concern and IPO news: Kardigan prices IPO of 25,000,000 shares at $16.00. Kardigan, Inc. (NASDAQ: KARD), United States."
---

KARD Kardigan, Inc. NASDAQ · United States

# Kardigan (KARD) news KARD going concern and IPO news

Financings · 2026-06-18

## [Kardigan prices IPO of 25,000,000 shares at $16.00](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/)

Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.

## Latest Kardigan news

1. 2026-05-26 Financings [Kardigan files for IPO, plans Nasdaq Global Market listing as KARD](https://aibio.space/news/kardigan-files-ipo-plans-nasdaq-global-market-listing-kard/) Kardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.

## Kardigan at a glance

- **Ticker**: KARD

- **Listing**: NASDAQ

- **Country**: United States

### Related companies

- [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) NASDAQ: KLRS
- [CAMP4 Therapeutics](https://aibio.space/companies/camp4-therapeutics/) NASDAQ: CAMP
- [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX
- [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY
- [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO
- [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC
- [VirExit Technologies](https://aibio.space/companies/virexit-technologies/) OTC: VXIT
- [Neutra](https://aibio.space/companies/neutra/) OTC: NTRR

### Also on NASDAQ

- [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) KYTX
- [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX
- [REPLIGEN CORP](https://aibio.space/companies/repligen/) RGEN
- [Quoin Pharmaceuticals](https://aibio.space/companies/quoin-pharmaceuticals/) QNRX
- [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA
- [Belite Bio](https://aibio.space/companies/belite-bio/) BLTE

## Questions about Kardigan

Has Kardigan issued a going-concern warning?

Our latest story on this, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

When did Kardigan go public?

Our latest story on this, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

What is the ticker symbol of Kardigan?

Kardigan, Inc. trades under the ticker KARD on NASDAQ.

Where is Kardigan listed?

Kardigan, Inc. is listed on NASDAQ.

What is the SEC CIK of Kardigan?

The SEC Central Index Key (CIK) for Kardigan, Inc. is 2123613. Its filings are on SEC EDGAR.

How many shares does Kardigan have outstanding?

93,503,699 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.

Which country or territory is Kardigan listed under?

Our directory records Kardigan, Inc. under United States.

What does Kardigan do?

Our directory classifies Kardigan, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Kardigan?

The ISIN recorded for Kardigan, Inc. is US4859251013.

Does aibio.space cover Kardigan?

aibio.space lists Kardigan, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Kardigan incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Kardigan (KARD) stock news?

Our latest story on Kardigan, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

What is Kardigan's latest stock offering or financing news?

Our latest financing story, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

Who were the underwriters or placement agents on Kardigan's offering?

From our story: J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are named on the cover as underwriters. [Source](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

How long will Kardigan's cash last?

From our story of Jun 18, 2026: The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/).

## Investor discussion: Kardigan

Members talk about Kardigan (KARD). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Kardigan, newest first. Each line links the filing it comes from.

1. 2026-08-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/2123613/000119312526343418/ck0002123613-20260630.htm)
2. 2026-06-18 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2123613/000119312526276096/d107928d424b4.htm)
3. 2026-05-26 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2123613/000119312526239298/d107928ds1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KARD on TradingView](https://www.tradingview.com/symbols/NASDAQ-KARD/).

## SEC filings and registration

- **SEC name**: Kardigan, Inc.

- **CIK**: 2123613

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: KARD (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: C/O KARDIGAN, INC., SOUTH SAN FRANCISCO, CA, 94080

- **Phone**: (415) 573-3220

- **Shares outstanding**: 93,503,699 as of 2026-08-07 (10-Q filed 2026-08-11)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/2123613/000119312526408348/ck0002123613-20260929.htm) filed 2026-09-30
- [10-Q](https://www.sec.gov/Archives/edgar/data/2123613/000119312526343418/ck0002123613-20260630.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-20260811.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/2123613/000119312526278429/d114621d8k.htm) filed 2026-06-23
- [S-1](https://www.sec.gov/Archives/edgar/data/2123613/000119312526239298/d107928ds1.htm) filed 2026-05-26

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002123613), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Kardigan, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KARD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Kardigan, Inc.

- **Ticker**: KARD

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US4859251013

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KARD/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/kardigan/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kardigan (KARD) news: going concern and IPO", 2026-10-31, https://aibio.space/companies/kardigan/
